Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

    The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

    The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

      Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up

      Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.

        Is a Beat in Store for Alexion (ALXN) This Earnings Season?

        Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

          Sweta Killa headshot

          Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

          Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

            Tirthankar Chakraborty headshot

            Will Midterms Throw Markets Helter-Skelter? 5 Top Picks

            In the last 11 midterm election years since 1974, the S&P 500 managed to eke out gains in April, but, mostly traded flat through September only to rally once political uncertainty waned.

              Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

              Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

                Sweta Killa headshot

                NYSE to Soon Greet The Fearless Girl Statue

                The Fearless Girl statue, a global symbol of female business prowess, is moving in front of the New York Stock Exchange by the end of this year.

                  What's in the Cards for Glaxo (GSK) This Earnings Season?

                  Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

                    Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                    Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                      Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

                      Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

                        3 Dividend ETFs With High Inflows in April

                        Consider these three dividend ETFs to fend off growing market uncertainty.

                          5 Drug Stocks Poised to Surpass on Earnings This Quarter

                          The outlook for the upcoming first-quarter results looks bright.

                            Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better

                            Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.

                              What's in Store for Novartis (NVS) This Earnings Season?

                              We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.

                                J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

                                J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

                                  Shire Sells Oncology Unit Ahead of Takeda's Potential Offer

                                  Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.

                                    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

                                    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

                                      Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug

                                      Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.

                                        Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus

                                        With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.

                                          Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

                                          Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

                                            Neena Mishra headshot

                                            Top ETF Picks for Your IRA

                                            Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.

                                              Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

                                              Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

                                                AbbVie's RA Candidate Meets Primary Endpoints in Phase III

                                                AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

                                                  Agios Pharmaceuticals Shares Rise on Buyout Speculation

                                                  Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.